ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Indy Hematology Review 2025: State of the Art 2025 - Emerging Therap…

Indy Hematology Review 2025

R. Birhiray

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlig…

2024 ASH Annual Meeting Insights Hub

J. Zeidner

Indy Hematology Review 2025: Treatment Options for Newly Diagnosed A…

Indy Hematology Review 2025

D. Pollyea

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

What’s New in AML: Treatment Advances and Key Trials in 2024

OncoAlert

F. Haddad

Indy Hematology Review 2025: Current and Emerging Therapies for Rela…

Indy Hematology Review 2025

R. Komrokji

Understanding the AML Disease State: Key Challenges and Advances

Cleveland Clinic Taussig Cancer Institute

M. Mustafa Ali

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Long-Term Follow-Up of the VIALE-A Study: Survival Outcomes and Subg…

Walter Fiedler

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Advancements in AML Management in 2024

Louisville Hematology Highlights

C. Lachowiez

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ASH 2025 Review: FLT3 Inhibitors in AML - Updates and Comparative In…

University of Colorado Division of Hematology

M. Angelos

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

What’s New in AML in 2025

Scripps Health

G. Yaghmour